NRx Pharmaceuticals, Inc. (NRXP)

NRx Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Selling, General & Admin	14.22	27.31	74.94	11.44	2.77
Research & Development	13.37	17.03	20.26	10.63	3.5
Other Operating Expenses	0.25	0	20.6	29.33	0
Operating Expenses	27.84	44.34	115.8	51.39	6.26
Operating Income	-27.84	-44.34	-115.8	-51.39	-6.26
Interest Expense / Income	0.12	0	0.02	0.06	0.3
Other Expense / Income	2.19	-4.58	-22.75	0.33	0.16
Pretax Income	-30.15	-39.75	-93.06	-51.78	-6.73
Net Income	-30.15	-39.75	-93.06	-51.78	-6.73
Preferred Dividends	0.01	0	255.82	0	0
Net Income Common	-30.16	-39.75	-348.89	-51.78	-6.73
Shares Outstanding (Basic)	8	7	5	3	1
Shares Outstanding (Diluted)	8	7	5	3	1
Shares Change	15.20%	40.17%	36.90%	220.58%	308.88%
EPS (Basic)	-4.00	-6.00	-19.80	-15.10	-6.30
EPS (Diluted)	-4.00	-6.00	-19.80	-15.10	-6.30
Free Cash Flow	-21.66	-39.77	-37.71	-2.27	-5.55
Free Cash Flow Per Share	-2.86	-6.05	-8.04	-0.66	-5.19
EBITDA	-30.03	-39.75	-93.04	-51.72	-6.43
Depreciation & Amortization	0.01	0	0	0	0
EBIT	-30.03	-39.75	-93.05	-51.72	-6.43

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).